Steris has penned a deal to acquire surgical safety solutions developer, Xodus Medical, for $2.1bn – adding a range of speciality healthcare consumable products to its portfolio as it sees continued sales growth in this area.
Through this agreement, which will see Steris buy all of Xodus’ equity primarily with debt, the former absorb the latter’s full range of surgical products, which span the realm of patient positioning innovations, sterile processing tools and single-use operating room (OR) essentials.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company is primarily recognised for its Pink Pad product, which is designed to optimally position a patient and prevent unwanted movement in the steep Trendelenburg position, which surgeons primarily use when conducting pelvic or lower abdominal procedures. To build on the Pink Pad’s legacy, Xodus recently debuted the Hot Pink Pad, which is designed to continuously monitor and control a patient’s temperature during surgery.
According to Steris’ president and CEO, Dan Carestio, the addition of consumables used in the operating room (OR) will particularly “complement and expand” the company’s offering within this space.
Carestio also highlighted the commercial potential of Xodus’ business, which he says has “demonstrated an ability to grow at double-digit rates”.
Meanwhile, Xodus touted the potential of Steris’ “extensive resources, industry knowledge, and established market presence”, which the company says could help grow its global standing in the healthcare space. Currently, Xodus, a privately owned company, is anticipating revenue of around $245m for 2026.
Steris’ call to acquire Xodus comes as the former company sees success from its range of healthcare consumables and services, with this segment of its business posting 10% growth year-on-year in Q2 2026.
In a research note, Jefferies analysts stated that “short-term demand signals derived from healthcare consumables orders [for Steris] remain healthy.”
Aside from its Xodus acquisition, the company has placed significant investments into its consumables capacity in recent months. In August, the company invested $600m to build a healthcare and pharma-centric formulated chemistries manufacturing and distribution centre in North Carolina, which will support its sterilisation and disinfection offerings. This was the largest manufacturing investment the company had made in its history.
